WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
2.
TauerA., KnerrT., NiwaT., SchaubT.P., LageC., Passlick-DeetjenJ.In vitro formation of n[epsilon]-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis.Biochem Biophys Res Commun2001; 280: 1408–14.
3.
DaviesS.J.Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?Nephrol Dial Transplant2009; 24: 2620–2.
4.
TranaeusA.A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution—clinical benefits. The Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20: 516–23.
5.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
6.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
7.
MontenegroJ., SarachoR.M., MartinezI.M., MunozR.I., OcharanJ.J., ValladaresE.Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions.Perit Dial Int2006; 26: 89–94.
8.
SzetoC.C., ChowK.M., LamC.W.K., LeungC.B., KwanB.C.H., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
9.
ChoiH.Y., KimD.K., LeeT.H., MoonS.J., HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
10.
FanS.L.S., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2007; 73: 200–6.
11.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
12.
VisserC.E., Brouwer-SteenbergenJ.J.E., BetjesM.G.H., KoomenG.C.M., BeelenR.H.J., KredietR.T.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
13.
SelgasR., BajoA., Jimenez-HeffernanJ.A., Sanchez-TomeroJ.A., del PesoG., AguileraA.Epithelial-to-mesenchymal transition of the mesothelial cell—its role in the response of the peritoneum to dialysis.Nephrol Dial Transplant2006; 21(Suppl 2): ii2–7.
14.
SummersA.M.Encapsulating peritoneal sclerosis—have we found the perpetrator?Perit Dial Int2009; 29: 499–501.
15.
TopleyN., MichaelD., BowenT.CA125: holy grail or a poisoned chalice.Nephron Clin Pract2005; 100: c52–4.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
18.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
19.
De VrieseA.S., MortierS., LameireN.H.Neoangiogenesis in the peritoneal membrane: does it play a role in ultrafiltration failure?Nephrol Dial Transplant2001; 16: 2143–5.
